EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

EGPA, which was formerly known as Churg-Strauss syndrome, affects roughly 118,000 people worldwide and can often be ...

AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...

Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic ...

It is also approved in children and adolescents ages six and above in the US and Japan. EGPA, formerly known as Churg-Strauss Syndrome, is a rare, immune-mediated inflammatory disease that is caused ...

Medically reviewed by Jurairat J. Molina, MDMedically reviewed by Jurairat J. Molina, MD Severe asthma symptoms can include ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

After two years, the Philippines' “Queen of All Media” Kris Aquino is back. In an Instagram post last Thursday (September 12) ...

Actress and TV host Kris Aquino returned to the Philippines early Friday morning, after years of seeking treatment for her ...

AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...